VLS Valneva SE

VALNEVA Declaration of shares and voting rights: October 31, 2025

VALNEVA Declaration of shares and voting rights: October 31, 2025

VALNEVA

Declaration of shares and voting rights

October 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: November 5, 2025

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 171,958,275



ordinary shares with a par value of €0.15 each		187,846,678Transfer into bearer form of 235,387 shares with double voting rights

 Definitive attribution of 103,419 free ordinary shares		Between October 3 & October 30, 2025









On October 10, 2025		187,722,356

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/11/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Declaration of shares and voting rights: October 31, 2025

VALNEVA Declaration of shares and voting rights: October 31, 2025 VALNEVA Declaration of shares and voting rights October 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: November 5, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal numbe...

2h / 37m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025

VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025 VALNEVA Déclaration d’actions et de droits de vote 31 octobre 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 5 novembre 2025 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variationDate à laquelle cette variation a été ...

2h / 37m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Reports Positive Results for Phase 1 Trial of Second-Generatio...

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). The randomized controlled Phase 1 trial, VLA1601-102, enrolled approximately 150 parti...

November 4, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva annonce des résultats positifs de Phase 1 pour son candidat va...

Valneva annonce des résultats positifs de Phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika   Réponse immunitaire améliorée avec le candidat vaccin de deuxième génération Saint-Herblain (France), le 4 novembre 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui des résultats positifs de Phase 1 évaluant l’innocuité et l’immunogénicité de VLA1601, son candidat vaccin inactivé et adjuvanté de seconde génération contre le virus Zika (ZIKV). L’essai de Phase 1, VLA1601-102, incluait environ 150 particip...

November 4, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and Eur...

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Saint-Herblain (France), October 27, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.  Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company’s Ly...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch